MarketCap
Facebook
X
Telegram
Catalyst Pharmaceuticals ROA Ratio | CPRX
Annual ROA Ratio Catalyst Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.41 | 19.25 | 15.19 | 22.12 | 16.6 | 38.98 | 28.36 | -56.25 | -21.56 | -43.33 | -33.66 | -35.32 | -47.91 | -24.28 | -102.27 | -68.7 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.98 | -102.27 | -17.09 |
Quarterly ROA Ratio Catalyst Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.18 | 22.31 | 23.06 | 21.3 | 15.06 | 7.61 | 10.44 | 11.92 | 8.32 | 15.15 | 30.68 | 27.54 | 20.28 | 24.9 | 23.9 | 19.7 | 14.34 | 36.87 | 37.33 | 36.92 | 33.04 | 40.09 | 29.69 | 34.36 | 28.36 | -2.68 | -27.77 | -47.4 | -56.25 | -38.57 | -30.5 | -25.18 | -21.56 | -25.24 | -29.82 | -36.23 | -43.33 | -43.03 | -40.95 | -37.58 | -33.66 | -31.94 | -35.94 | -35.64 | -35.32 | -32.71 | -44.61 | -49.71 | -47.91 | -43.03 | -35.34 | -24.67 | -24.28 | -61.46 | -63.89 | -84.48 | -102.27 | -18.05 | -22.31 | -24.28 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 40.09 | -102.27 | -12.7 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
-80.09 | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
-49.15 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-121.84 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-22.28 | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
-56.95 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-136.72 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-27.51 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-54.04 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-74.47 | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
1.36 | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-55.34 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
1.78 | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
-15.57 | - | - | $ 83.9 M | Canada |
 |
Liquidia Corporation
LQDA
|
-21.02 | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
-93.5 | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
-14.64 | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
7.83 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-161.0 | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-341.56 | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-106.53 | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-29.82 | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
7.97 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
18.35 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
TCR2 Therapeutics
TCRR
|
-72.91 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-41.31 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
-176.62 | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
-13.02 | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
19.74 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-28.79 | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
0.74 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-6.89 | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
26.31 | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
13.34 | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
-22.87 | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
-428.94 | - | -16.42 % | $ 249 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
2.77 | - | - | $ 2.02 B | USA |
 |
Intellia Therapeutics
NTLA
|
-49.01 | $ 11.18 | -7.72 % | $ 1.21 B | USA |
 |
Novartis AG
NVS
|
12.59 | $ 163.39 | -0.18 % | $ 317 B | Schweiz |
 |
Omeros Corporation
OMER
|
-1.03 | $ 17.3 | -1.48 % | $ 1.1 B | USA |
 |
Oramed Pharmaceuticals
ORMP
|
27.74 | $ 3.97 | -0.75 % | $ 164 M | Israel |
 |
Tyme Technologies
TYME
|
-26.84 | - | 8.07 % | $ 54 M | USA |
 |
Puma Biotechnology
PBYI
|
14.38 | $ 8.13 | -3.22 % | $ 407 M | USA |